srd5a1

SRD5A1-IN-1 is an inhibitor of steroid 5α-reductase type 1 (SRD5A1, IC50 = 1.44 µM). SRD5A1-IN-1 lowers the production of dihydrotestosterone and shows a significant decrease in the SRD5A1 protein expression.

Lapisteride (CS-891) a steroidal 5α-reductase inhibitor is used to treat benign prostatic hyperplasia (BPH) and androgenetic alopecia and may be effective in preventing or treating AGA .

Levonorgestrel (D-Norgestrel) is a Progestin and Progestin-containing Intrauterine Device. The physiologic effect of levonorgestrel is by means of Inhibit Ovum Fertilization.

SRD5A1-IN-2 is a steroid 5α-reductase type 1 (SRD5A1) inhibitor with an IC50 of 8.5 μM. It decreases the expression of the SRD5A1 protein in HaCaT cells and reduces the production of dihydrotestosterone (DHT) in these cells. This compound may be utilized in the study of androgen-related disorders such as androgenetic alopecia (AGA).